NeuroSense Therapeutics Ltd.
NRSNNASDAQHealthcare● Active
$0.75
+$0.00(+0.20%)
Market Cap$18539466
P/E Ratio—
52W High$2.6
52W Low$0.63
NeuroSense Therapeutics Ltd. (NRSN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NRSN · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 6, 2026EPS Actual
-$0.23
Est. -$0.07 · -231.9%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 6, 2026
After Market Close
▼ Miss EPS
NRSN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | Jun 30, 2026 | -$0.20 | — | — | — | $0.00B | — |
| ◌ Q2 FY2026 | Jun 22, 2026 | -$0.08 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | Apr 6, 2026 | -$0.07 | -$0.23 | -231.9% | — | — | — |
| — Q4 FY2025 | Dec 17, 2025 | — | -$0.11 | — | — | — | — |
| ▼ Q2 FY2025 | May 28, 2025 | -$0.10 | -$0.11 | -4.8% | — | — | — |
| ▲ Q2 FY2025 | Apr 7, 2025 | -$0.11 | -$0.06 | +45.5% | — | — | — |
| ▲ Q4 FY2024 | Dec 18, 2024 | -$0.16 | -$0.11 | +31.3% | — | — | — |
| ▲ Q3 FY2024 | Sep 30, 2024 | -$0.20 | -$0.02 | +90.0% | — | — | — |
Q2 FY2026
Jun 30, 2026
EPS Actual
—
EPS Est.
-$0.20
EPS Surpr.
—
Revenue
—
Q2 FY2026
Jun 22, 2026
EPS Actual
—
EPS Est.
-$0.08
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 6, 2026Miss
EPS Actual
-$0.23
EPS Est.
-$0.07
EPS Surpr.
-231.9%
Revenue
—
Q4 FY2025
Dec 17, 2025
EPS Actual
-$0.11
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 28, 2025Miss
EPS Actual
-$0.11
EPS Est.
-$0.10
EPS Surpr.
-4.8%
Revenue
—
Q2 FY2025
Apr 7, 2025Beat
EPS Actual
-$0.06
EPS Est.
-$0.11
EPS Surpr.
+45.5%
Revenue
—
Q4 FY2024
Dec 18, 2024Beat
EPS Actual
-$0.11
EPS Est.
-$0.16
EPS Surpr.
+31.3%
Revenue
—
Q3 FY2024
Sep 30, 2024Beat
EPS Actual
-$0.02
EPS Est.
-$0.20
EPS Surpr.
+90.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Q3 FY2028 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Q2 FY2028 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q1 FY2028 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q4 FY2027 | $-0.51 | $-0.51 | $-0.51 | 1 |
| Q3 FY2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 6, 2026 | -231.9% | $0.83 | $0.76 | -8.19% |
| — Q4 FY2025 | Dec 17, 2025 | — | $0.85 | $0.83 | -2.35% |
| ▼ Q2 FY2025 | May 28, 2025 | -4.8% | $1.52 | $1.58 | +3.95% |
| ▲ Q2 FY2025 | Apr 7, 2025 | +45.5% | $0.99 | $0.97 | -2.02% |
| ▲ Q4 FY2024 | Dec 18, 2024 | +31.3% | $1.09 | $1.14 | +4.59% |
| ▲ Q3 FY2024 | Sep 30, 2024 | +90.0% | $1.28 | $1.27 | -0.78% |
| ▲ Q2 FY2024 | Apr 5, 2024 | +20.0% | $2.06 | $1.70 | -17.48% |
| ▲ Q1 FY2024 | Mar 22, 2024 | +20.0% | $1.81 | $1.76 | -2.76% |
Q2 FY2026-8.19%
Report Date
Apr 6, 2026
EPS Beat/Miss
-231.9%
Price Before
$0.83
Price After
$0.76
Q4 FY2025-2.35%
Report Date
Dec 17, 2025
EPS Beat/Miss
—
Price Before
$0.85
Price After
$0.83
Q2 FY2025+3.95%
Report Date
May 28, 2025
EPS Beat/Miss
-4.8%
Price Before
$1.52
Price After
$1.58
Q2 FY2025-2.02%
Report Date
Apr 7, 2025
EPS Beat/Miss
+45.5%
Price Before
$0.99
Price After
$0.97
Q4 FY2024+4.59%
Report Date
Dec 18, 2024
EPS Beat/Miss
+31.3%
Price Before
$1.09
Price After
$1.14
Q3 FY2024-0.78%
Report Date
Sep 30, 2024
EPS Beat/Miss
+90.0%
Price Before
$1.28
Price After
$1.27
Q2 FY2024-17.48%
Report Date
Apr 5, 2024
EPS Beat/Miss
+20.0%
Price Before
$2.06
Price After
$1.70
Q1 FY2024-2.76%
Report Date
Mar 22, 2024
EPS Beat/Miss
+20.0%
Price Before
$1.81
Price After
$1.76
Avg Beat Reaction-3.69%
Avg Miss Reaction-2.12%
Beat Rate5 / 8 quarters
Largest Move-17.48% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NRSN ends December
NeuroSense Therapeutics Ltd. (NRSN) most recently reported earnings on April 6, 2026 for Q2 FY2026, posting EPS of $-0.23 — missing the analyst consensus of $-0.07 by -231.9%. The next NRSN earnings date is expected around September 1, 2026.
Each quarter, investors track NRSN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NRSN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NRSN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NRSN earnings · 5 questionsNeuroSense Therapeutics Ltd.'s next earnings report is expected around September 1, 2026. NRSN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NRSN historically reports after market close (AMC).
NRSN earnings datewhen is NRSN earningsNRSN next earnings datewhen does NRSN report earningsNRSN earnings calendar
▸ Source: FMP · NeuroSense Therapeutics Ltd. SEC filings · US GAAP · NeuroSense Therapeutics Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026